
In this phase I study, we added escalating doses of zzso 2A zzso to zzso and zzso zzso based on the following zzso zzso enhancement has been shown for both zzso and zzso in addition, zzso of the zzso activity of zzso by zzso has been zzso A total of 48 patients with advanced solid tumors were treated with zzso in 2 daily zzso of 125 zzso plus zzso at 8-10 zzso per day delivered on 3 different schedules zzso infusion, daily short-term infusion, and single short-term infusion of 50 zzso zzso was injected zzso 2 h preceding the first daily fraction of zzso zzso doses ranged from 0 to zzso zzso zzso zzso per zzso All therapy was given over 5 days of every other week until completion of the zzso Treatment at all dose levels was well tolerated during cycles 1 and 2, with no instance of acute grade 3 or 4 toxicity being zzso However, cumulative zzso in patients receiving more than two treatment cycles was seen at all dose levels and was attributed to the repeated administration of zzso zzso of the zzso schedule did not allow for further dose escalation of zzso Our recommended doses are zzso given at 8 zzso per day as a continuous infusion with zzso at zzso zzso zzso zzso per zzso Among 24 patients with zzso lung cancer, 2 had a complete response, 9 had a partial response, and 7 had stable zzso We conclude that this zzso zzso regimen is zzso zzso was seen in zzso lung cancer, and further studies of this regimen in that disease appear zzso 

